10 results on '"Hayden Doughty"'
Search Results
2. Vesiculobullous Lyme disease: A case series
- Author
-
Hayden Doughty, BS, Keegan O’Hern, MD, Dorothea T. Barton, MD, and Joi B. Carter, MD
- Subjects
bacteria ,bacterial infection ,infection ,insect ,insect bite ,Lyme disease ,Dermatology ,RL1-803 - Published
- 2022
- Full Text
- View/download PDF
3. Severe nonanaphylactic allergic reaction to the Pfizer-BioNTech COVID-19 vaccine
- Author
-
Hayden Doughty, BS and Dorothea Barton, MD
- Subjects
allergy ,COVID-19 ,COVID-19 vaccine ,edema ,morbilliform rash ,vaccine reaction ,Dermatology ,RL1-803 - Published
- 2022
- Full Text
- View/download PDF
4. Adnexotropic and granulomatous mycosis fungoides following <scp>TNF</scp> ‐α inhibitor treatment
- Author
-
Hayden Doughty, Andrew Scripture, Joi B. Carter, Aravindhan Sriharan, Shaofeng Yan, Frederick Lansigan, and Shabnam Momtahen
- Subjects
Histology ,Dermatology ,Pathology and Forensic Medicine - Published
- 2023
5. Magnetic Resonance Imaging Screening after Silicone Implant Breast Surgery: Patient Survey of Adherence to U.S. Food and Drug Administration Recommendations
- Author
-
Libby R, Copeland-Halperin, Ariel T, Wampler, Hayden, Doughty, Nina, Shank, Joshua J, Levy, Maria L, Reategui Via Y Rada, and Joseph M, Rosen
- Subjects
Silicone Gels ,United States Food and Drug Administration ,Breast Implants ,Surveys and Questionnaires ,Silicones ,Humans ,Breast Neoplasms ,Female ,Surgery ,Magnetic Resonance Imaging ,United States ,Prosthesis Failure - Abstract
The U.S. Food and Drug Administration recommends women with silicone breast implants undergo magnetic resonance imaging surveillance to detect asymptomatic rupture. Screening is costly and often not covered by insurance. The authors assessed awareness of and adherence to these recommendations among patients with silicone breast implants.The authors searched electronic medical records for patients aged 18 years or older with silicone breast implants placed between 2011 and 2016. Consenting patients were surveyed by telephone using a standardized script to assess awareness of U.S. Food and Drug Administration recommendations, whether they had undergone magnetic resonance imaging screening, and barriers to testing. Patients who declined to participate or could not be contacted were excluded. Demographics and operative data were collected. Odds ratios were calculated with one-sample 95 percent confidence intervals, and Fisher exact tests of independence were conducted under assumptions of normality. Multivariable logistic regression analysis was performed to test for confounding.Of 370 patients meeting inclusion criteria, 109 consented to participate. Adherence to U.S. Food and Drug Administration recommendations was 5.9 percent (95 percent CI, 0.15 to 28.7 percent). There was no difference in adherence between patients undergoing cosmetic versus reconstructive surgery ( p = 1.00; OR, 0.80; 95 percent CI, 1.17 to 2.93), having health insurance ( p = 0.58), or residing in a county with median annual household income greater than that of the state of residence ( p = 0.33).A small proportion of respondents had undergone magnetic resonance imaging in accordance with U.S. Food and Drug Administration recommendations. Low adherence highlights a potential limitation of current federal surveillance recommendations. Additional research is needed to better characterize adherence to magnetic resonance imaging surveillance recommendations, identify barriers to implementation, and determine whether this recommendation remains valid.
- Published
- 2022
6. Severe nonanaphylactic allergic reaction to the Pfizer-BioNTech COVID-19 vaccine
- Author
-
Dorothea T. Barton and Hayden Doughty
- Subjects
medicine.medical_specialty ,Allergic reaction ,Coronavirus disease 2019 (COVID-19) ,business.industry ,vaccine reaction ,MEDLINE ,COVID-19 ,Case Report ,Dermatology ,morbilliform rash ,allergy ,RL1-803 ,Medicine ,business ,COVID-19 vaccine ,edema - Published
- 2022
7. Analgesic Use Following Bilateral Breast Reduction
- Author
-
Ian A. Powelson, Ariel T. Wampler, Hayden Doughty, Alec H. Fisher, and Gary L. Freed
- Subjects
Narcotic ,Mammaplasty ,medicine.medical_treatment ,Analgesic ,030230 surgery ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Prospective Studies ,Analgesics ,Pain, Postoperative ,business.industry ,Hydromorphone ,Acetaminophen ,Analgesics, Opioid ,030220 oncology & carcinogenesis ,Anesthesia ,Ambulatory ,Surgery ,Tramadol ,Breast reduction ,business ,Oxycodone ,medicine.drug - Abstract
The opioid epidemic in the United States resulted in 42,000 deaths in 2016, 40% of which involved a prescription opioid. It is estimated that 2 million patients become opioid-dependent after elective, ambulatory surgery each year. There has been increased interest in quantifying the need for postoperative narcotic pain medications for a variety of surgical procedures. However, studies have been limited. We sought to quantify the analgesic usage after one of the most common operations performed in plastic surgery, bilateral breast reduction.In this prospective, observational study, sequential breast reduction patients were contacted by telephone on the evening of postoperative days 3 and 7. Patients were queried as to which analgesic medications were used on the day of the phone call. Data relating to dosage, frequency, and satisfaction with pain control were sought. Patients taking chronic narcotics, postoperative complications requiring surgical intervention, and those unable to be reached after multiple attempts were excluded.Complete data were obtained for 40 patients. Narcotic prescriptions were written for oxycodone, hydromorphone and tramadol, with the number prescribed ranging from 0 to 20 tablets. The median total number used was 6 tablets. Eighty percent of patients used a total of 10 tablets or less. Fifty percent of patients were using only nonnarcotic analgesia by postoperative day 3. Patient-reported satisfaction with pain control was overwhelmingly positive, with 95% being either somewhat satisfied or very satisfied with postoperative pain control. Of those taking any medication on postoperative day 3, only half were using a nonsteroidal anti-inflammatory drug (NSAID) as part of their pain regimen.The number of tablets prescribed after breast reduction surgery varies considerably, and there is no consensus regarding the appropriate number to prescribe. Currently, few patients use all the medication prescribed to them, indicating a high rate of overprescribing. The overwhelming majority are satisfied with their pain control. Most patients use less than 10 tablets of narcotic pain medication after surgery. Acetaminophen is widely used as an adjunct but NSAIDs remain underutilized. Based on these data, we recommend that breast reduction patient's pain is best managed with acetaminophen, NSAIDs, and expectation management.
- Published
- 2020
8. Creating a Value Dashboard for Orthopaedic Surgical Procedures
- Author
-
Connor W Rockwell, Paul M. Werth, Hayden Doughty, Michael B. Sparks, Clifford A. Reilly, and David S. Jevsevar
- Subjects
musculoskeletal diseases ,Male ,medicine.medical_specialty ,Quality Assurance, Health Care ,medicine.medical_treatment ,Arthroplasty, Replacement, Hip ,Dashboard (business) ,MEDLINE ,Periprosthetic ,Patient Readmission ,Indirect costs ,Health care ,Medicine ,Humans ,Orthopedics and Sports Medicine ,Patient Reported Outcome Measures ,Arthroplasty, Replacement, Knee ,Aged ,Quality Indicators, Health Care ,Quality of Health Care ,business.industry ,General Medicine ,Middle Aged ,Arthroplasty ,surgical procedures, operative ,Value (economics) ,Physical therapy ,Surgery ,Female ,business ,Quality assurance - Abstract
Background Value-based health-care delivery is a framework for restructuring our health-care systems with the goal of providing better outcomes for patients at lower cost. Value is determined by patient health outcomes per dollar spent on health services. We sought to develop a value dashboard that could be used to easily track and improve the value of total hip and knee arthroplasty (THA and TKA). Methods We created a value dashboard for TKAs and THAs at our institution. Value was defined as quality of outcomes per dollar spent. The dashboard for each procedure displayed the average value by surgeon, compared with institutional averages for physical function scores and cost. Quality metrics were determined by weighted surgeon ranking using a modified Delphi process and included both clinical and patient-reported outcomes, as measured by the mean change in the Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10) physical function score, mean change in the Hip disability and Osteoarthritis Outcome Score-Joint Replacement (HOOS-JR) or the Knee injury and Osteoarthritis Outcome Score-Joint Replacement (KOOS-JR), mean change in the modified Single Assessment Numeric Evaluation (SANE) score, complication rate, periprosthetic joint infection (PJI) rate, and 30-day readmission rate. Average direct costs per surgeon were used. Data from January 2017 through April 2018 were included to ensure 1-year follow-up. Results Six surgeons were included in the value dashboard for TKA, and 5 were included in the THA dashboard. The value for TKA by surgeon ranged from 7% below to 12% above the institutional benchmark. The value for THA by surgeon ranged from 12% below to 7% above the institutional benchmark. Conclusions The proposed dashboard utilizes value in a health-care framework and could be used for comparing and improving value for THA and TKA. This dashboard successfully combined patient outcome metrics and direct costs of surgical procedures. Future studies should focus on involving patients in this process and using national data to create benchmarks, which could provide a more accurate representation of value than using institutional averages.
- Published
- 2020
9. Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells
- Author
-
Jason Kenealey, Hayden Doughty, John Lawson, Richard Oblad, and Merrill J. Christensen
- Subjects
Male ,0301 basic medicine ,Drug ,Cell Survival ,media_common.quotation_subject ,Docetaxel ,03 medical and health sciences ,chemistry.chemical_compound ,Prostate cancer ,0302 clinical medicine ,Piperidines ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Piperlongumine ,Cell Proliferation ,media_common ,Flavonoids ,Pharmacology ,Mitoxantrone ,Models, Statistical ,Chemistry ,Prostatic Neoplasms ,Dioxolanes ,Drug Synergism ,Combination chemotherapy ,medicine.disease ,030104 developmental biology ,Resveratrol ,Cabazitaxel ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,Molecular Medicine ,Taxoids ,medicine.drug - Abstract
Combining chemotherapeutics to treat malignant tumors has been shown to be effective in preventing drug resistance, tumor recurrence, and reducing tumor size. We modeled combination drug therapy in PC-3 human prostate cancer cells using mixture design response surface methodology (MDRSM), a statistical technique designed to optimize compositions that we applied in a novel manner to design combinations of chemotherapeutics. Conventional chemotherapeutics (mitoxantrone, cabazitaxel, and docetaxel) and natural bioactive compounds (resveratrol, piperlongumine, and flavopiridol) were used in 12 different combinations containing three drugs at varying concentrations. Cell viability and cell cycle data were collected and used to plot response surfaces in MDRSM that identified the most effective concentrations of each drug in combination. MDRSM allows for extrapolation of data from three or more compounds in variable ratio combinations, unlike the Chou-Talalay method. MDRSM combinations were compared with combination index data from the Chou-Talalay method and were found to coincide. We propose MDRSM as an effective tool in devising combination treatments that can improve treatment effectiveness and increase treatment personalization, because MDRSM measures effectiveness rather than synergism, potentiation, or antagonism.
- Published
- 2018
10. The Effects of 4′-Esterified Resveratrol Derivatives on Calcium Dynamics in Breast Cancer Cells
- Author
-
Hayden Doughty, Trent A Johnson, Merritt B. Andrus, Joshua Allen Peterson, Jason Kenealey, Austin James Eells, Jordan Hastings, and Colton M. Crowther
- Subjects
p53 ,0301 basic medicine ,MDA-MB-231 ,Pharmaceutical Science ,Resveratrol ,Analytical Chemistry ,chemistry.chemical_compound ,0302 clinical medicine ,Stilbenes ,Drug Discovery ,skin and connective tissue diseases ,Calcium signaling ,Molecular Structure ,Esters ,Receptors, Estrogen ,Biochemistry ,Chemistry (miscellaneous) ,030220 oncology & carcinogenesis ,resveratrol derivatives ,Molecular Medicine ,Female ,Cell Survival ,chemistry.chemical_element ,Antineoplastic Agents ,Biology ,Calcium ,calcium signaling ,Article ,lcsh:QD241-441 ,03 medical and health sciences ,Breast cancer ,lcsh:Organic chemistry ,Cell Line, Tumor ,medicine ,Humans ,Viability assay ,cell viability ,Physical and Theoretical Chemistry ,Cell Proliferation ,Organic Chemistry ,medicine.disease ,In vitro ,030104 developmental biology ,chemistry ,Cancer cell ,Cancer research ,Breast cancer cells - Abstract
Triple-negative breast cancer is a highly aggressive subtype of breast cancer. Frequently, breast cancer cells modulate their calcium signaling pathways to optimize growth. Unique calcium pathways in breast cancer cells could serve as a way to target tumorigenic cells without affecting normal tissue. Resveratrol has previously been shown to activate calcium signaling pathways. We use cell viability, single-cell calcium microscopy, and RT-PCR assays to determine the activity and mechanism of three different 4′-esterified resveratrol derivatives. We demonstrate that two of the derivatives reduce cell viability more effectively than resveratrol in MDA-MB-231 human breast cancer cells. The derivatives also activate similar pro-apoptotic calcium signaling pathways. In particular, the pivalated and butyrated resveratrol derivatives are intriguing putative chemotherapeutics because they are more effective at decreasing cell viability in vitro and inhibiting the plasma membrane Ca2+-ATPase, a protein that is often modulated in breast cancer.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.